News | September 02, 2023
Biocon acquires oral solid dosage manufacturing facility of Eywa Pharma for US$7.7 million
The facility has a potential for capacity expansion up to 2 billion tablets/capsules per year
The facility has a potential for capacity expansion up to 2 billion tablets/capsules per year
Exothera will manufacture Meissa’s MV-012-968 vaccine candidate under CGMP regulations to supply Phase 2 clinical trials
Under the terms of the collaboration, Vertex and Lonza will partner in the process development and scale-up for the manufacturing of the product portfolio and co-invest to build a dedicated new facility in Portsmouth, New Hampshire (US)
Carbogen Amcis Manchester won the industry award in recognition of its efficiency improvement program implemented in response to increased demand for its products
The inspection closed with the facility receiving an inspection classification of NAI
The company will submit its comprehensive response on these observations to the US FDA
Samsung Biologics will provide Pfizer with additional capacity for large-scale manufacturing for a multi-product biosimilars portfolio
New facility will strengthen the security of supply for global pharmaceutical and biotech customers and will support the continued development and production of lifesaving clinical and commercial-scale therapeutics for patients worldwide.
Construction will begin this year with the new capacity anticipated by 2025
The US FDA in its communication mentioned it may withhold approval of any pending applications or supplements in which this facility is listed.
Subscribe To Our Newsletter & Stay Updated
